These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 26134280)

  • 1. Reaching women where they are: eliminating the initial in-person medical abortion visit.
    Raymond EG; Grossman D; Wiebe E; Winikoff B
    Contraception; 2015 Sep; 92(3):190-3. PubMed ID: 26134280
    [TBL] [Abstract][Full Text] [Related]  

  • 2. If we can do it for misoprostol, why not for mifepristone? The case for taking mifepristone out of the office in medical abortion.
    Gold M; Chong E
    Contraception; 2015 Sep; 92(3):194-6. PubMed ID: 26093187
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparing two early medical abortion regimens: mifepristone+misoprostol vs. misoprostol alone.
    Ngoc NT; Blum J; Raghavan S; Nga NT; Dabash R; Diop A; Winikoff B
    Contraception; 2011 May; 83(5):410-7. PubMed ID: 21477682
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Outpatient medical abortion is safe and effective through 70 days gestation.
    Abbas D; Chong E; Raymond EG
    Contraception; 2015 Sep; 92(3):197-9. PubMed ID: 26118638
    [TBL] [Abstract][Full Text] [Related]  

  • 5. TelAbortion: evaluation of a direct to patient telemedicine abortion service in the United States.
    Raymond E; Chong E; Winikoff B; Platais I; Mary M; Lotarevich T; Castillo PW; Kaneshiro B; Tschann M; Fontanilla T; Baldwin M; Schnyer A; Coplon L; Mathieu N; Bednarek P; Keady M; Priegue E
    Contraception; 2019 Sep; 100(3):173-177. PubMed ID: 31170384
    [TBL] [Abstract][Full Text] [Related]  

  • 6. The costs and cost effectiveness of providing second-trimester medical and surgical safe abortion services in Western Cape Province, South Africa.
    Lince-Deroche N; Constant D; Harries J; Kluge J; Blanchard K; Sinanovic E; Grossman D
    PLoS One; 2018; 13(6):e0197485. PubMed ID: 29953434
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A prospective, non-randomized study of home use of mifepristone for medical abortion in the U.S.
    Chong E; Frye LJ; Castle J; Dean G; Kuehl L; Winikoff B
    Contraception; 2015 Sep; 92(3):215-9. PubMed ID: 26142620
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [The efficacy and acceptability of mifepristone medical abortion with home administration misoprostol provided by private providers linked with the hospital: a prospective study of 433 patients].
    Faucher P; Baunot N; Madelenat P
    Gynecol Obstet Fertil; 2005 Apr; 33(4):220-7. PubMed ID: 15894206
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The mifepristone-misoprostol regimen for early medical abortion.
    Ellertson C; Waldman SN
    Curr Womens Health Rep; 2001 Dec; 1(3):184-90. PubMed ID: 12112968
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Acceptability and feasibility of mifepristone medical abortion in the early first trimester in Azerbaijan.
    Louie KS; Tsereteli T; Chong E; Aliyeva F; Rzayeva G; Winikoff B
    Eur J Contracept Reprod Health Care; 2014 Dec; 19(6):457-64. PubMed ID: 25047120
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Management of missed abortion: comparison of medical treatment with either mifepristone + misoprostol or misoprostol alone with surgical evacuation. A multi-center trial in Copenhagen county, Denmark.
    Grønlund A; Grønlund L; Clevin L; Andersen B; Palmgren N; Lidegaard Ø
    Acta Obstet Gynecol Scand; 2002 Nov; 81(11):1060-5. PubMed ID: 12421175
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Mifepristone by prescription: a dream in the United States but reality in Australia.
    Grossman D; Goldstone P
    Contraception; 2015 Sep; 92(3):186-9. PubMed ID: 26096369
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Early medical abortion: a new regimen up to 49 days' gestation.
    Ashima T; Vinita A; Shalini R
    Aust N Z J Obstet Gynaecol; 2005 Apr; 45(2):137-9. PubMed ID: 15760315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Efficacy and safety of mifepristone and buccal misoprostol versus buccal misoprostol alone for medical abortion.
    Dahiya K; Ahuja K; Dhingra A; Duhan N; Nanda S
    Arch Gynecol Obstet; 2012 Apr; 285(4):1055-8. PubMed ID: 22009509
    [TBL] [Abstract][Full Text] [Related]  

  • 15. A review of evidence for safe abortion care.
    Kapp N; Whyte P; Tang J; Jackson E; Brahmi D
    Contraception; 2013 Sep; 88(3):350-63. PubMed ID: 23261233
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Current medical abortion care.
    Creinin MD
    Curr Womens Health Rep; 2003 Dec; 3(6):461-9. PubMed ID: 14613667
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Acceptability and feasibility of mifepristone-misoprostol for menstrual regulation in Bangladesh.
    Alam A; Bracken H; Johnston HB; Raghavan S; Islam N; Winikoff B; Reichenbach L
    Int Perspect Sex Reprod Health; 2013 Jun; 39(2):79-87. PubMed ID: 23895884
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A two-stage increase in the dose of misoprostol improves the efficacy of medical abortion with mifepristone and prostaglandins.
    Aubeny E
    Eur J Contracept Reprod Health Care; 2001 Mar; 6(1):54-5. PubMed ID: 11334477
    [No Abstract]   [Full Text] [Related]  

  • 19. Minimal effective dose of mifepristone for medical abortion.
    Kapoor G; Salhan S; Sarda N; Aggarwal D
    J Indian Med Assoc; 2014 Feb; 112(2):96-9. PubMed ID: 25935963
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Termination of pregnancy at 9-13 weeks' amenorrhoea with mifepristone and misoprostol.
    Ashok PW; Flett GM; Templeton A
    Lancet; 1998 Aug; 352(9127):542-3. PubMed ID: 9716062
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.